Abstract
Introduction Catatonia is a highly morbid psychomotor and affective disorder which can affect autistic individuals with and without profound impairment. Catatonic symptoms are treatable with pharmacotherapy and electroconvulsive therapy, but the longitudinal effectiveness of these treatments has not been described.
Methods We conducted a prospective observational cohort study of patients with autism and co-morbid catatonia who received outpatient care in a specialized outpatient clinic from July 1st, 2021 to May 31st, 2024. Data investigating pharmacologic interventions, and clinical measures including the Bush Francis Catatonia Rating Scale (BFCRS), Kanner Catatonia Severity Scale (KCS), Kanner Catatonia Examination (KCE), and Clinical Global Impression – Improvement (CGI-I) were collected.
Results Forty-five patients were identified with 39 (86.7%) meeting criteria for profound autism. All patients received pharmacotherapy. 44 (97.8%) were treated with benzodiazepines with a mean maximal daily dose of 17.4 mg (SD=15.8) lorazepam equivalents. Thirty-five patients (77.8%) required more than one medication class for treatment. Fourteen patients (31.1%) attempted to taper off benzodiazepines during the study period; of these, 5 patients (11.1%) were successfully tapered off, and the remaining 9 (17.8%) discontinued the taper due to a return of catatonic symptoms. Statistically significant improvement was observed across all clinical domains except the KCS. However, the majority remained symptomatic over the study period.
Conclusions Despite clinical improvements while receiving the gold standard for psychopharmacologic management of catatonia, chronic symptoms remained for the majority of catatonia patients over the study period, and few were able to taper and discontinue benzodiazepine treatment.
Lay Summary Catatonia is a condition which can significantly impact the quality of life for autistic individuals with and without profound impairment. Symptoms of catatonia such as aggression and self-injury can improve with treatment. However, over the three-year period of this study, most patients experienced residual symptoms, and few could discontinue psychotropic medication.
Competing Interest Statement
JRS receives funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Axial Therapeutics, and Roche. ZJW has received consulting fees from Roche and Autism Speaks. He also serves as the Vice-chair of Autistic and Neurodivergent Scholars Working for Equity in Research (ANSWER), a division of the Autism Intervention Research Network on Physical Health (AIR-P). JW receives support from the Department of Veterans Affairs, Geriatric, Research, Education and Clinical Center (GRECC) at the Tennessee Valley Healthcare System in Nashville, TN. JL receives funding from Harvard Medical School, the Rappaport Foundation, and the Foundation for Prader-Willi Research. He holds equity and has received consulting income from Revival Therapeutics, Inc.
Funding Statement
Sources of support included grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (1P50HD103537; JRS), the National Institute on Deafness and Other Communication Disorders (F30-DC019510; ZJW), the National Institute of General Medical Sciences (T32-GM007347; ZJW), and Vanderbilt University Medical Center Bixler-Johnson-Mayes Endowed Chair in the Department of Psychiatry and Behavioral Sciences (SL, CF). No funding agencies had any role in study design, writing of the report, or data collection, analysis, or interpretation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed by the Vanderbilt University Institutional Review Board (#170317) with a waiver of informed consent from participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts of Interest Statement: JRS receives funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Axial Therapeutics, and Roche. ZJW has received consulting fees from Roche and Autism Speaks. He also serves as the Vice-chair of Autistic and Neurodivergent Scholars Working for Equity in Research (ANSWER), a division of the Autism Intervention Research Network on Physical Health (AIR-P). JW receives support from the Department of Veterans Affairs, Geriatric, Research, Education and Clinical Center (GRECC) at the Tennessee Valley Healthcare System in Nashville, TN. JL receives funding from Harvard Medical School, the Rappaport Foundation, and the Foundation for Prader-Willi Research. He holds equity and has received consulting income from Revival Therapeutics, Inc.
Funding: Sources of support included grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (1P50HD103537; JRS), the National Institute on Deafness and Other Communication Disorders (F30-DC019510; ZJW), the National Institute of General Medical Sciences (T32-GM007347; ZJW), and Vanderbilt University Medical Center Bixler-Johnson-Mayes Endowed Chair in the Department of Psychiatry and Behavioral Sciences (SL, CF). No funding agencies had any role in study design, writing of the report, or data collection, analysis, or interpretation.
Data Availability
De-identified data is available from the corresponding author (JRS) upon reasonable request
Abbreviations
- (ECT)
- Electroconvulsive Therapy
- (STROBE)
- Strengthening the Reporting of Observational Studies in Epidemiology
- (BFCRS)
- Bush Francis Catatonia Rating Scale
- (KCS)
- Kanner Catatonia Severity
- (KCE)
- Kanner Catatonia Examination
- (BFCSI)
- Bush Francis Catatonia Screening Item
- (CGI-I)
- Clinical Global Impression–Improvement
